AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2442957 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine restricted diet
Number of subjects: 9
Study 2442957 — intervention group
Group type: COMPARATOR
Intervention: Free diet with tyrosine (160 mg/kg/24 h)
Number of subjects: 9
Study 2442957 — intervention group
Group type: COMPARATOR
Intervention: Free diet supplemented with tyrosine
Number of subjects: 9
Study 30788529 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 30 mg
Number of subjects: 30
Study 30788529 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 75 mg
Number of subjects: 30
Study 30788529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29735006 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA matching
Number of subjects: 721
Study 29735006 — intervention group
Group type: COMPARATOR
Intervention: Random graft assignment (Control)
Number of subjects: 721
Study 27991018 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional mesh for prevention
Number of subjects: 116
Study 27991018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mesh) for prevention
Number of subjects: 116
Study 27991018 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional mesh for repair
Number of subjects: 116
Study 27991018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mesh) for repair
Number of subjects: 116
Study 24450968 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous diagnosis of depression
Number of subjects: 1085
Study 24450968 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor vision (as determined from a Visual Function Questionnaire)
Number of subjects: 1085
Study 24450968 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor vision (in subgroup without previous diagnosis of depression)
Number of subjects: 1085
Study 22648715 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary polyamine intake (above the median amount)
Number of subjects: 1164
Study 20146136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training (experimental treatment)
Number of subjects: 12
Study 20146136 — intervention group
Group type: COMPARATOR
Intervention: Non-specific cognitive training (control)
Number of subjects: 12
Study 18357573 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of girls with adolescent onset of bipolar disorder
Number of subjects: 44
Study 18357573 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of boys with childhood onset of bipolar disorder
Number of subjects: 44
Study 15938028 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Participation (PP) program
Number of subjects: 165
Study 15938028 — intervention group
Group type: COMPARATOR
Intervention: Standard Consultation (SC)
Number of subjects: 165
Study 12570122 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin (400 mg o.d.)
Number of subjects: 564
Study 12570122 — intervention group
Group type: COMPARATOR
Intervention: Standard oral therapy (amoxicillin 1 g t.i.d. or clarithromycin 500 mg b.i.d. alone or in combination)
Number of subjects: 564
Study 12570122 — intervention group
Group type: COMPARATOR
Intervention: Standard oral therapy (amoxicillin or clarithromycin)
Number of subjects: 564
Study 10475293 — intervention group
Group type: EXPERIMENTAL
Intervention: epinephrine 0.5 microg/kg group
Number of subjects: 80
Study 10475293 — intervention group
Group type: EXPERIMENTAL
Intervention: epinephrine 0.25 microg/kg group
Number of subjects: 80
Study 10475293 — intervention group
Group type: EXPERIMENTAL
Intervention: epinephrine 0.125 microg/kg group
Number of subjects: 80
Study 10475293 — intervention group
Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 80
Study 8946270 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice a day for 12 months
Number of subjects: 0
Study 1751442 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave Doppler studies of umbilical and uteroplacental arterial circulations
Number of subjects: 505
Study 6126961 — intervention group
Group type: COMPARATOR
Intervention: celiprolol (100 mg t.i.d.)
Number of subjects: 21
Study 6126961 — intervention group
Group type: COMPARATOR
Intervention: propranolol (40 mg t.i.d.)
Number of subjects: 21
Study 6126961 — intervention group
Group type: COMPARATOR
Intervention: celiprolol
Number of subjects: 21
Study 6126961 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 21
Study 6126961 — intervention group
Group type: COMPARATOR
Intervention: celiprolol and propranolol
Number of subjects: 21
Study 31103444 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 0
Study 31103444 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictions
Number of subjects: 0
Study 31103444 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29710119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 167
Study 29710119 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure lowering
Number of subjects: 167
Study 26881251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranirestat 20 mg once daily
Number of subjects: 0
Study 24708851 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Decongestive Therapy including manual drainage
Number of subjects: 160
Study 24708851 — intervention group
Group type: COMPARATOR
Intervention: Complete Decongestive Therapy without manual lymphatic drainage
Number of subjects: 160
Study 22769857 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracet (37.5 mg tramadol/325 mg APAP)
Number of subjects: 60
Study 22769857 — intervention group
Group type: COMPARATOR
Intervention: Depain‐X (65 mg propoxyphene/650 mg APAP)
Number of subjects: 60
Study 20144496 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (1 mL) plus Ringer lactate during arthroscopy
Number of subjects: 40
Study 20144496 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate during arthroscopy
Number of subjects: 40
Study 17184378 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-based search strategy
Number of subjects: 0
Study 17184378 — intervention group
Group type: COMPARATOR
Intervention: Free text search strategy
Number of subjects: 0
Study 17184378 — intervention group
Group type: COMPARATOR
Intervention: Thesaurus search strategy
Number of subjects: 0
Study 15850471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg Talpha1 monotherapy
Number of subjects: 316
Study 15850471 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg Talpha1 monotherapy
Number of subjects: 316
Study 12399722 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol red thread test (PRT)
Number of subjects: 54
Study 12399722 — intervention group
Group type: COMPARATOR
Intervention: Schirmer I test
Number of subjects: 54
Study 10365315 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practices
Number of subjects: 50
Study 7675981 — intervention group
Group type: COMPARATOR
Intervention: Inositol as sole therapy for depression
Number of subjects: 49
Study 7675981 — intervention group
Group type: COMPARATOR
Intervention: Inositol for panic disorder
Number of subjects: 49
Study 2167789 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion at 20 degrees C for 2 min
Number of subjects: 11
Study 2167789 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion at 0-4 degrees C for 2 min
Number of subjects: 11
Study 2167789 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic for two periods of 2 min
Number of subjects: 11
Study 7148050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.0 mg/kg body weight)
Number of subjects: 9
Study 7148050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (1.5 mg/kg body weight)
Number of subjects: 9
Study 29857075 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Mousse (CPP‐ACP group)
Number of subjects: 12
Study 29857075 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (control group)
Number of subjects: 12
Study 27914519 — intervention group
Group type: EXPERIMENTAL
Intervention: Study formula with DHASCO®-B (17mg DHA/100kcal)
Number of subjects: 267
Study 27914519 — intervention group
Group type: EXPERIMENTAL
Intervention: Study formula with DHASCO®-B
Number of subjects: 267
Study 27914519 — intervention group
Group type: COMPARATOR
Intervention: Control formula (DHASCO®)
Number of subjects: 267
Study 25659477 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 25
Study 25659477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 23686414 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 755
Study 23686414 — intervention group
Group type: COMPARATOR
Intervention: Immediate combination therapy
Number of subjects: 755
Study 23686414 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX monotherapy (step-up at 24 weeks)
Number of subjects: 755
Study 20158090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg to 45 mg)
Number of subjects: 5238
Study 20158090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5238
Study 20158090 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (1 to 4 mg)
Number of subjects: 5238
Study 18258791 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical esophageal lidocaine (15 ml)
Number of subjects: 55
Study 18258791 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior mucosal acid exposure
Number of subjects: 55
Study 18258791 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon distension
Number of subjects: 55
Study 18258791 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (40 mg orally)
Number of subjects: 55
Study 16636123 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg potassium perchlorate daily
Number of subjects: 13
Study 16636123 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg potassium perchlorate daily
Number of subjects: 13
Study 16636123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 14679692 — intervention group
Group type: EXPERIMENTAL
Intervention: New fistula on the same vascular level (Group I, N=56)
Number of subjects: 274
Study 14679692 — intervention group
Group type: EXPERIMENTAL
Intervention: Fistula at a higher level (Group II, N=31)
Number of subjects: 274
Study 10671828 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologist's structured 10-session intervention program for 20 weeks
Number of subjects: 0
Study 10671828 — intervention group
Group type: COMPARATOR
Intervention: Control group (C-ward)
Number of subjects: 0
Study 10167366 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal smoking cessation intervention
Number of subjects: 127
Study 10167366 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking puffs in late pregnancy
Number of subjects: 127
Study 10167366 — intervention group
Group type: EXPERIMENTAL
Intervention: Having friends who smoke at the first prenatal visit
Number of subjects: 127
Study 10167366 — intervention group
Group type: EXPERIMENTAL
Intervention: Less confidence in mid‐pregnancy about maintaining nonsmoking postpartum
Number of subjects: 127
Study 10167366 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner who smokes postpartum
Number of subjects: 127
Study 1437861 — intervention group
Group type: EXPERIMENTAL
Intervention: Red low level narrow band (LLNB) light (660 nm)
Number of subjects: 21
Study 1437861 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared LLNB light (940 nm)
Number of subjects: 21
Study 1437861 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no light irradiation)
Number of subjects: 21
Study 2867560 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg naproxen sodium initially and then 275 mg naproxen sodium 4-times daily
Number of subjects: 68
Study 2867560 — intervention group
Group type: COMPARATOR
Intervention: 100 mg dextropropoxyphene napsylate initially and then 100 mg dextropropoxyphene napsylate 4-times daily
Number of subjects: 68
Study 30129062 — intervention group
Group type: COMPARATOR
Intervention: Bilateral lateral approach
Number of subjects: 8
Study 30129062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventral cervical approach
Number of subjects: 8
Study 26550959 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus PMT
Number of subjects: 94
Study 26550959 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 94
Study 24553997 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid (2,000 mg of eicosapentaenoic acid and docosahexaenoic acid)
Number of subjects: 45
Study 24553997 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-linoleic acid (borage oil containing 400 mg γ-linoleic acid)
Number of subjects: 45
Study 24553997 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 24430037 — intervention group
Group type: EXPERIMENTAL
Intervention: Stalevo
Number of subjects: 73
Study 24430037 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy people)
Number of subjects: 73
Study 20533764 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SR) 2 g/day
Number of subjects: 152
Study 20533764 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 70 mg/week
Number of subjects: 152
Study 20533764 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SR)
Number of subjects: 152
Study 20533764 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 152
Study 18649895 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent endovascular stent-graft placement
Number of subjects: 6
Study 15867181 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/d)
Number of subjects: 20
Study 15867181 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (10 mg/d)
Number of subjects: 20
Study 12952834 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with 1.0 mg/kg body weight of recombinant alpha‐Gal A (agalsidase beta, Fabrazyme) for 12 months
Number of subjects: 16
Study 10389781 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.2 microg x kg(‐1) x min(‐1) with desflurane 3.2%‐3.6%
Number of subjects: 115
Study 10389781 — intervention group
Group type: COMPARATOR
Intervention: Nonopiate with desflurane 7%‐9%
Number of subjects: 115
Study 8877074 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 100
Study 8877074 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 100
Study 8877074 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 150 mg
Number of subjects: 100
Study 8877074 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 100
Study 8877074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2058987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) treatment
Number of subjects: 35
Study 2058987 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 35
Study 2058987 — intervention group
Group type: COMPARATOR
Intervention: Behçet group
Number of subjects: 35
Study 2058987 — intervention group
Group type: COMPARATOR
Intervention: Behçet group and uveitis group
Number of subjects: 35
Study 4089261 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I permanent implant
Number of subjects: 0
Study 4089261 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I permanent implant with external beam radiotherapy ('boost'-therapy)
Number of subjects: 0
Study 30640484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary intervention (EMI) that taught stress management skills for 14 days
Number of subjects: 382
Study 30640484 — intervention group
Group type: COMPARATOR
Intervention: Ecological momentary assessment (EMA) with self-monitoring of stressors and mood for 14 days
Number of subjects: 382
Study 29084101 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-hour manualized small group cognitive-behavioral intervention
Number of subjects: 35
Study 29084101 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 35
Study 26385162 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week teacher-delivered intervention focused on healthy lifestyle behaviors
Number of subjects: 618
Study 26385162 — intervention group
Group type: COMPARATOR
Intervention: 14-week teacher-delivered general health curriculum (control group)
Number of subjects: 618
Study 25248797 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (weekly trainer-led group exercise sessions, instructed home exercise 3-5 times/week during 20-36 weeks of gestation, dietary counseling twice during pregnancy)
Number of subjects: 116
Study 25248797 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 116
Study 25248797 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 116
Study 22446296 — intervention group
Group type: COMPARATOR
Intervention: APG101 (20 mg/kg) administered as infusion over 1 hour to healthy volunteers
Number of subjects: 36
Study 22446296 — intervention group
Group type: COMPARATOR
Intervention: APG101 (5 mg to 600 mg) administered intravenously to glioma patients
Number of subjects: 36
Study 22446296 — intervention group
Group type: COMPARATOR
Intervention: APG101 (400 mg) administered weekly to glioma patients
Number of subjects: 36
Study 20942275 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Sanyinjiao (SP 6) for 30 min
Number of subjects: 174
Study 20942275 — intervention group
Group type: COMPARATOR
Intervention: Placebo treated group (moxibustion at no acupoint for 30 min)
Number of subjects: 174
Study 20942275 — intervention group
Group type: COMPARATOR
Intervention: Blank group (routine labor nursing)
Number of subjects: 174
Study 20942275 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Sanyinjiao (SP 6)
Number of subjects: 174
Study 20942275 — intervention group
Group type: COMPARATOR
Intervention: Placebo treated group
Number of subjects: 174
Study 20942275 — intervention group
Group type: COMPARATOR
Intervention: Blank group
Number of subjects: 174
Study 20942275 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Sanyinjiao (SP 6) and Placebo treated group
Number of subjects: 174
Study 16015414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 211
Study 16015414 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 211
Study 12708123 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard exercise test (Modified Harvard Step-Test) at 2100 m and 4350 m
Number of subjects: 20
Study 12708123 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise test (Modified Harvard Step-Test) at 4350 m
Number of subjects: 20
Study 10393400 — intervention group
Group type: EXPERIMENTAL
Intervention: n-acetylcysteine (NAC) in combination with streptokinase
Number of subjects: 0
Study 10393400 — intervention group
Group type: EXPERIMENTAL
Intervention: n-acetylcysteine (NAC)
Number of subjects: 0
Study 8601931 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 2459
Study 8601931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2459
Study 2004539 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 183
Study 2004539 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 183
Study 2004539 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 20 mg
Number of subjects: 183
Study 2004539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 6599496 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (AII) infusion at 7.5 ng/kg/min
Number of subjects: 7
Study 6599496 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (P)
Number of subjects: 7
Study 6599496 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (AII) infusion
Number of subjects: 7
Study 29271504 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI
Number of subjects: 56
Study 29271504 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced liver fibrosis (ELF) test
Number of subjects: 56
Study 29271504 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness
Number of subjects: 56
Study 29271504 — intervention group
Group type: COMPARATOR
Intervention: Multiparametric MRI compared to biopsy
Number of subjects: 56
Study 29271504 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI combined with transient elastography
Number of subjects: 56
Study 27940182 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic carrier screening
Number of subjects: 0
Study 27940182 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25559916 — intervention group
Group type: EXPERIMENTAL
Intervention: NOURISH-T intervention
Number of subjects: 0
Study 25559916 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) control
Number of subjects: 0
Study 23134084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursolic acid liposomes (UAL) at doses of 11, 22, 37, 56, 74, 98, and 130 mg/m(2) administered as a 4-h intravenous infusion
Number of subjects: 63
Study 23134084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursolic acid liposomes (UAL)
Number of subjects: 63
Study 21607939 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic full access (SFA) to the medical record
Number of subjects: 0
Study 21607939 — intervention group
Group type: COMPARATOR
Intervention: Requested access (RA) to the medical record
Number of subjects: 0
Study 18311687 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg amitriptyline
Number of subjects: 40
Study 18311687 — intervention group
Group type: COMPARATOR
Intervention: 40 mg paroxetine
Number of subjects: 40
Study 18311687 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 40
Study 16573703 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg once daily
Number of subjects: 1974
Study 16573703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1974
Study 12699032 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 87
Study 12699032 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 87
Study 12699032 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 87